Biologic Therapy
ACR praises FDA plan to end switching study requirement for interchangeable biosimilars
The American College of Rheumatology has applauded an FDA proposal to streamline the approval of interchangeable biosimilars, removing requirements for switching studies to determine their interchangeability with reference products.
Guselkumab de-escalation maintains psoriasis control in patients with early skin clearance
In patients with early and complete clearance of psoriasis, extending the guselkumab dosing interval to every 16 weeks maintained disease control as well as an 8-week interval, according to a study published in JAMA Dermatology.
Asthma remission appears possible with treatment
SAN ANTONIO — Clinicians and researchers are beginning to explore whether asthma remission is possible, Corinne Young, FNP-C, FCCP, said during her presentation at the 16th Annual Allergy, Asthma & Immunology CME Conference.
Biologic therapy impacts body composition in severe asthma
Adults with severe asthma using a biologic therapy for the first time experienced changes in body composition parameters at 1 year, according to a research letter published in Annals of the American Thoracic Society.
Human umbilical cord tissue allograft may treat cartilage degeneration, hip OA
Use of cryopreserved human umbilical cord tissue, known as Wharton’s jelly, may be an alternative treatment for tissue regeneration in patients with hip cartilage defects and osteoarthritis, according to published results.
Patients, clinicians support use of as-needed biologic therapy for psoriasis
Patients and clinicians agree that as-needed use of biologic therapy has benefits over continuous long-term biologic use for the treatment of psoriasis, according to a study.